Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06212193 · ClinicalTrials.gov registry record · NA

Innoventric Trillium™ Stent Graft Early Feasibility Study (EFS)

A NA study of Tricuspid Regurgitation and Tricuspid Regurgitation Functional, sponsored by Innoventric.

Recruiting
Registry status
NA
Development phase
15
Enrollment target
12
Study locations

NCT06212193 is a NA study of Tricuspid Regurgitation and Tricuspid Regurgitation Functional that is actively recruiting participants, run by Innoventric. The registered enrollment target is 15 participants, below the 535-participant average among 17 other Tricuspid Regurgitation trials with a reported enrollment target (97% lower). The trial reports 12 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06212193, a NA study of Tricuspid Regurgitation and Tricuspid Regurgitation Functional, is actively recruiting participants, sponsored by Innoventric.

RECRUITING
Registry status
NA
Development phase
15 participants
Enrollment target
12
Study locations

Study Summary

Early Feasibility Study to evaluate the safety and performance of the Innoventric Trillium™ Stent Graft in the treatment of severe or greater tricuspid regurgitation (TR).

Interventions

  • DEVICE Trillium™

Study Locations (12)

New York

  • Weill Cornell Medicine - New York
  • Stony Brook Heart Institute - Stony Brook

California

  • Cardiovascular Institute of Los Robles Health System - Thousand Oaks

Michigan

  • Ascension St. John - Detroit

Minnesota

  • Mayo Clinic Hospital (Rochester) - Rochester

Ohio

  • The Christ Hospital - Cincinnati

Pennsylvania

  • Lankenau Heart Institute - Philadelphia

Tennessee

  • TriStar Centennial Medical Center - Nashville

Washington

  • University of Washington Medical Center - Seattle

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2024-08-05
Est. Completion 2030-08
Phase NA

Sponsor

Innoventric

1 total trials

What the Registry Record Tells You About NCT06212193

The ClinicalTrials.gov registry entry for NCT06212193 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 535-participant average among 17 other Tricuspid Regurgitation trials with a reported enrollment target (97% lower). The listed sponsor is Innoventric, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Tricuspid Regurgitation appearing as the primary indexed condition, and to 1 intervention - of which Trillium™ is the first listed.

NCT06212193 reports 12 study locations spanning 11 distinct geographic areas - top geographies include New York, California, Michigan.

Frequently Asked Questions

What is clinical trial NCT06212193 about?

NCT06212193 is a clinical study titled "Innoventric Trillium™ Stent Graft Early Feasibility Study (EFS)". Early Feasibility Study to evaluate the safety and performance of the Innoventric Trillium™ Stent Graft in the treatment of severe or greater tricuspid regurgitation (TR).

What is the current status of trial NCT06212193?

This trial is currently recruiting. It is a NA study. The enrollment target is 15 participants. The study started on 2024-08-05. Estimated completion is 2030-08.

What conditions does trial NCT06212193 study?

This clinical trial studies the following conditions: Tricuspid Regurgitation, Tricuspid Regurgitation Functional.

What interventions are being tested in trial NCT06212193?

The interventions under investigation include: Trillium™ (DEVICE).

Who is sponsoring clinical trial NCT06212193?

This trial is sponsored by Innoventric, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06212193 being conducted?

This trial has 12 study locations across California, Michigan, Minnesota, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Tricuspid Regurgitation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.